Health Condition 1: G939- Disorder of brain, unspecified
Conditions
Interventions
None listed
Sponsors
Institute of Training and Research in Ayurveda
Eligibility
Inclusion criteria
Inclusion criteria: Subjects irrespective of gender, fulfilling the criteria of Mild Neurocognitive Disorder as per DSM V. Age group of 55 to 80 years Participants should demonstrate independency in daily living activities, with minimal assistance required. A score between 18 to 25 on the Montreal Cognitive assessment scale. Patients willing to provide inform consent, comply with the study protocol, including attending follow-up visits and participating in assessments throughout the study duration.
Exclusion criteria
Exclusion criteria: Age below 55 years and above 80 years. A score less than 18 and more than 25 on the Montreal Cognitive assessment scale. Subjects with major depression or other psychiatric disorders or currently undergoing treatment for depression. Cognitive impairment is attributable to other identifiable causes (e.g.traumetic brain injury, acute infections) Individuals with other neurological disorders i.e. epilepsy, Parkinson s disease, Multiple sclerosis Use of psychoactive medication that would affect the subject s ability to reliably perform on neurocognitive testing. Individuals currently taking medications known to impact cognitive function(e.g. benzodiazepines, anticholinergics) History of substance abuse (alcohol, drugs) within the past year. Malignant disease, HIV or serious infection. Subjects with Cardiovascular, Renal or Hepatic disorder, Thyroid dysfunction. Subjects with uncontrolled HTN (Blood Pressure more than 150/100 mm of Hg) and Diabetes (RBS more than 200 mg/dl) Subjects who have decline in cognitive functions as a result of surgery. Visual/auditory impairment that would preclude the participant from participating in or cooperating with the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in the cognition, memory and language measured by Montreal Cognitive Assessment scaleTimepoint: Improvement in the cognition, memory and language measured by Montreal Cognitive Assessment scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in BDNF levels. Improvement in daily living activity based on Bristol Activities of Daily Living Scale. Improvement in Quality of life measured on Quality of Life in Alzheimer s disease scale. Timepoint: 60 days | — |
Countries
India
Contacts
Public ContactDr Mandip Goyal
Institute of Teaching and Research in Ayurveda
Outcome results
None listed